Private placement

2CRSi SA: 2CRSi announces the launch of a €8 to €12 million round of financing to accelerate its growth in the Artificial Intelligence server market

Retrieved on: 
Mercredi, avril 10, 2024
Private placement, Private, Corporate communication, European Parliament, Intelligence, Acceleration, Société Générale, BNP Paribas, Jeantet, Sale, Artificial intelligence, Combined, HAW, Euronext, Risk, Prospectus, Council, PEA, European, Pea, Calendar, NVIDIA, Security (finance)

The rise of artificial intelligence positions us perfectly to capture market opportunities driven by significant economic and environmental challenges.

Key Points: 
  • The rise of artificial intelligence positions us perfectly to capture market opportunities driven by significant economic and environmental challenges.
  • Fueled by the enthusiasm and commitment of our teams, we anticipate that 2024 will be a pivotal year.
  • This market, in which 2CRSi enjoys international recognition, is being driven by an explosion in global demand for high-performance server technology solutions and hosted computing power.
  • The Global Offer does not give rise to a prospectus subject to the approval of the Autorité des marchés financiers.

ArcStone Securities and Investments Corp. Announces Strategic Collaboration with Kingswood US to Deliver Expanded Capital Markets Advisory Services Establishing a Presence in the Canadian Capital Markets

Retrieved on: 
Mercredi, mars 13, 2024
Private placement, Culture, Public, Growth, Philosophy, Partnership, Executive officer, Metal, IPO, Equity, TSX, Investment, CBOE, Mining

This collaboration will enable clients to benefit from an expanded suite of services designed to drive value creation and advance their strategic objectives.

Key Points: 
  • This collaboration will enable clients to benefit from an expanded suite of services designed to drive value creation and advance their strategic objectives.
  • Collectively, ArcStone and Kingswood bring together a seasoned team in Canada and the US with a shared commitment to integrity and client success.
  • This marks a significant milestone for ArcStone and Kingswood in its unwavering commitment to providing comprehensive capital market solutions and strategic advisory services across a north-south nexus.
  • Pre-Initial Public Offering (Pre-IPO) Strategy: Initial Public Offering (IPO) Execution, Debt Capital Markets Access, Private Placements, and Private Capital Advisory.

Alamos and Argonaut Close Previously Announced Private Placement

Retrieved on: 
Jeudi, avril 4, 2024
Indian stock exchange, Private placement, Private, Common, AGI, Attention, Brookfield Place, Suite, TSX, Transaction, Security (finance)

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (“Alamos”) (TSX:AGI; NYSE:AGI) and Argonaut Gold Inc. (“Argonaut”) (TSX:AR) today announced the closing of their previously announced non-brokered private placement, pursuant to which Alamos subscribed (the “Private Placement”) for 174,825,175 common shares of Argonaut (the “Acquired Shares”), representing approximately 13.8% of Argonaut’s total outstanding common shares (the “Common Shares”) after giving effect to the Private Placement.

Key Points: 
  • TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (“Alamos”) (TSX:AGI; NYSE:AGI) and Argonaut Gold Inc. (“Argonaut”) (TSX:AR) today announced the closing of their previously announced non-brokered private placement, pursuant to which Alamos subscribed (the “Private Placement”) for 174,825,175 common shares of Argonaut (the “Acquired Shares”), representing approximately 13.8% of Argonaut’s total outstanding common shares (the “Common Shares”) after giving effect to the Private Placement.
  • The Private Placement was conducted pursuant to the terms of the arrangement agreement between Alamos and Argonaut entered into on March 27, 2024 (the “Arrangement Agreement”) pursuant to which Alamos will acquire all of the issued and outstanding shares of Argonaut pursuant to a court approved plan of arrangement (the “Transaction”).
  • Immediately prior to the closing of the Private Placement, Alamos did not have beneficial ownership of, or control or direction over, any Common Shares.
  • After giving effect to the Private Placement, Alamos has beneficial ownership of, or control or direction over, 174,825,175 Common Shares, or approximately 13.8% of the issued and outstanding Common Shares.

Carmell Announces $3.0 Million Private Placement

Retrieved on: 
Jeudi, avril 4, 2024
Private placement, Private, Sale, Skin, Financial services

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).

Key Points: 
  • PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).
  • The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of its common stock on the Nasdaq Capital Market on April 3, 2024.
  • Following the Closing of the Private Placement, Carmell will have approximately 20.58 million common shares outstanding.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the exclusive placement agent for the private placement transaction.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Vendredi, mars 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

ThreeD Capital Inc. Announces Completion of Private Placement with Sariel Diagnostics Corp.

Retrieved on: 
Samedi, mars 23, 2024
Private placement, IDK, Sariel, Private

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed its previously announced private placement (the “Private Placement”) with Sariel Diagnostics Corp. (“Sariel”), a privately held corporation existing under the laws of the Province of British Columbia.

Key Points: 
  • TORONTO, March 22, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK) (OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce that it has closed its previously announced private placement (the “Private Placement”) with Sariel Diagnostics Corp. (“Sariel”), a privately held corporation existing under the laws of the Province of British Columbia.
  • As a result of the Private Placement, ThreeD has acquired 3,750,000 common shares of Sariel at a price of $0.02 per share.
  • No commission or finders’ fees were paid in connection with the Private Placement.
  • All securities issued and issuable in connection with the Private Placement are subject to a statutory hold period expiring on July 23, 2024.

Major Announces Application for Partial Revocation Order

Retrieved on: 
Vendredi, mars 22, 2024
Unit, Legislation, Private placement, Bank statement, Private, BCSC, Security (finance)

If the partial revocation order is granted, the company intends to complete a non-brokered private placement of up to thirty million units (“Units”) issued at a price of $0.025 per Unit for gross proceeds of up to $750,000.

Key Points: 
  • If the partial revocation order is granted, the company intends to complete a non-brokered private placement of up to thirty million units (“Units”) issued at a price of $0.025 per Unit for gross proceeds of up to $750,000.
  • Each Unit will be comprised of one common share (each a “Share”) and one transferable common share purchase warrant (each a “Warrant”).
  • All of the Company's securities issued in connection with the Private Placement, will remain subject to the FFCTO until such order is fully revoked.
  • The granting of the partial revocation order by the BCSC does not guarantee the issuance of a full revocation order in the future.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Mercredi, mars 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Mercredi, mars 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

XTL To Aquire The Social Proxy

Retrieved on: 
Mercredi, mars 20, 2024
Private placement, Term sheet, Growth, Proxy, AI, ADS, Investment, IP, XTL, Transaction, Government, Security (finance)

RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) --  XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., (the “Social Proxy”) a cutting edge web data company, developing and powering a unique ethical, IP based, proxy and data extraction platform for AI & BI Applications at scale (the “Term Sheet”).

Key Points: 
  • RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) --  XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., (the “Social Proxy”) a cutting edge web data company, developing and powering a unique ethical, IP based, proxy and data extraction platform for AI & BI Applications at scale (the “Term Sheet”).
  • Shlomo Shalev, CEO of XTL commented: “We are pleased to add the Social Proxy into our asset portfolio and believe that it will add great value to our company and shareholders.
  • We are excited to add the Social Proxy technology to XTL.
  • Tal Kinger, CEO of The Social Proxy commented: “We are thrilled to become part of the XTL team and are confident that working under XTL and its management will accelerate our growth and value creation”.